Cargando…
Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
BACKGROUND: Little is known about the safety and efficacy of using two or more biologics for the treatment of immune-mediated diseases, including Crohn’s disease (CD). CASE SUMMARY: This case report and narrative review demonstrate the potential safety of dual biologic therapy (DBT) in a 45-year-old...
Autores principales: | Au, Michael, Mitrev, Nikola, Leong, Rupert W, Kariyawasam, Viraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968582/ https://www.ncbi.nlm.nih.gov/pubmed/35434082 http://dx.doi.org/10.12998/wjcc.v10.i8.2569 |
Ejemplares similares
-
Review of exclusive enteral therapy in adult Crohn’s disease
por: Mitrev, Nikola, et al.
Publicado: (2021) -
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017) -
Safety of dual biological therapy in Crohn’s disease: a case series of vedolizumab in combination with other biologics
por: Mao, Eric J, et al.
Publicado: (2018) -
Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018) -
Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)